

ISSN 2545-093X (print)
ISSN 2545-1073 (online)

ISSN №2 (2) 2018

INTERNATIONAL JOURNAL
OF NEW ECONOMICS, PUBLIC ADMINISTRATION AND LAW



INTERNATIONAL JOURNAL OF NEW ECONOMICS, PUBLIC ADMINISTRATION AND LAW

(IJONEPAAL)

№ 2 (2) 2018

The Journal is Listed and Indexed in Google Scholar, BASE (Zenodo), OJS, DOAJ, PKP Index, CrossRef, ORCID, e-LIBRARY (Researcher ID), SPIN, JIFactor

(Published Journal)	ISSN 2545-093X
(Online: www.ijoness.esy.es)	ISSN 2545-1073

Publisher

Cech Rzemiosł Różnych,
Dr hab. (economic sciences),
Professor

Zbigniew Sulżycki,
72-600, ul. Bohaterów
Września 4,
Świnoujście,
Polska,

email: ijonepaal@ukr.net,
<http://www.ijoness.esy.es>

Chief Editor

Dr hab., Professor
Alina Yakymchuk, Public Admin-
istration, Documentation and
Information Activities Depart-
ment of National University of
Water and Environmental Engi-
neering, 33028, Soborna St., 11,
Rivne, Ukraine,

e-mail: ijonepaal@ukr.net,
<http://www.ijoness.esy.es>

Partner

Varna Free University «Cher-
norizets Hrabar», Vice-Rector for
Scientific Research, Professor
Pavel Pavlov, 9007, Chayka Re-
sort, Varna, Bulgaria,

tel./Fax: +359 52 357 066,
phone: +359 52 359 513,
fax: +359 52 357 066,
e-mail: pavlov_p@vfu.bg
<http://www.vfu.bg/en>

Editorial Board:

- Editor-in-Chief – Dr hab. (economic sciences), Professor **Alina Yakymchuk** – Public Administration, Documentation and Information Activities Department of National University of Water and Environmental Engineering (Rivne) Ukraine;
- First Deputy Scientific Editor – Dr hab. (economic sciences), professor **Janusz Soboń**, Jacob of Paradise University in Gorzow Wielkopolski (Gorzow Wielkopolski) Poland;
- Second Deputy Scientific Editor – Dr (economic science), **Agnieszka Kister**, – Doctor of Faculty of Economics, Maria Curie-Sklodowska University in Lublin (Lublin) Poland;
- Subject Editor – Dr hab. (public administration), Professor **Mykola Koretskyi** – President of Company «Greek Group» (Kyiv) Ukraine;
- Scientific Editor – Doctor of Philosophy, Professor **Pavel Pavlov** – Vice-Rector for Scientific Research, Varna Free University «Chernorizets Hrabar» (Varna), Bulgaria;
- Subject Editor – Dr hab. (legal science), Professor **Sergey V. Arakelyan** – Rector of Academy of Justice (Yerevan) Republic of Armenia;
- Subject Editor – Dr hab. (economic sciences), Professor **Kanstantsin Shebeko** – Rector of the the Paliessie State University (Pinsk) Belarus;
- Subject Editor – Dr. hab. (economic sciences), Professor **Oleksandr Melnychenko** – Chairman of the Board at Consilium LLC (Warsaw) Poland;
- Subject Editor – Dr hab. (legal sciences), Professor **Roman Kaidashev**, Head of the Department of Law of Zhytomyr Institute «Higher Educational Institution «Interregional Academy of Personnel Management», Honored Economist of Ukraine, Cavalier of the Order «For Merits» III degree, Public servant of first rank in retirement (Zhytomyr) Ukraine;
- Subject Editor – Dr hab. (public administration), Professor **Svitlana Bila** – National Aviation University, Professor of the Department of International Economic Relations and Business (Kyiv) Ukraine;
- Subject Editor – Dr hab. (public administration, medical sciences), Professor **Sergiy Bugaytsov** – Chief Scientist of the Research Center of Civil Protection Measures of the Ukrainian Research Institute of Civil Protection (Kyiv) Ukraine;
- Subject Editor – PhD (social sciences), Professor **Anna Chabasińska** – Vice-Dean of the Faculty of Administration and National Security, Jacob of Paradise University in Gorzow Wielkopolski (Gorzow Wielkopolski) Poland;
- Subject Editor – Dr hab. (economic science), Professor **Natalia Savina** – Pro-rector on Scientific Work and International Relations of National University of Water and Environmental Engineering (Rivne) Ukraine;
- Subject Editor – Dr hab. (public administration) **Andriy Valyukh** – Professor of National University of Water and Environmental Engineering (Rivne) Ukraine;
- Doctor of Philosophy, PhD (in Law) **Oleksandr Shamara** – Deputy Head of Scientific-research institute National Protection Academy of Ukraine, Member of International Association of Penal Law (Kyiv) Ukraine;
- Statistical Editor – PhD (public administration), Professor **Oleksandr Akimov** – Head of Legal Support Department of National Mediation and Reconciliation Service, Department of Public Administration of the Interregional Academy of Personnel Management, Honored Economist of Ukraine (Kyiv) Ukraine;

Academic Committee:

- Dr hab. (economic sciences), Professor **Anatoliy Sokhnych** – Honored Worker of Science and Technology of Ukraine, The Head of the Land Management Department of Lviv National Agrarian University (Lviv) Ukraine;
- Dr hab. (economic sciences), Professor **Joanna Rogozińska-Mitrut** – the Faculty of Economics, Jacob of Paradise University in Gorzow Wielkopolski (Gorzow Wielkopolski) Poland;
- Dr hab. (economic sciences), Professor **Srikrishna Deva Rao** – Vice-Chancellor, National Law University of Odisha (Odisha) India;
- Dr hab. (economic sciences), Professor **Sergey Ohrimenko** – Academy of Economic Studies of Moldova, Head of the Laboratory of Information Security (Chisinau) Moldova;
- Dr hab. (legal sciences), **Robert Brumnik** – GEA-College (Ljubljana) Slovenia;
- PhD (economic sciences), Associate Professor **Iryna Zbornya** – The Dean of the Economical Faculty, Paliessie State University (Pinsk) Belarus;
- Dr hab. (public administration), Professor **Nataliia Goncharuk** – Honored Worker of Science and Technology of Ukraine, Department of Public Administration and Local Government of Dnipropetrovsk Regional Institute of Public Administration of the National Academy of Public Administration under the President of Ukraine (Dnipropetrovsk) Ukraine;
- PhD (economic sciences), Associate Professor **Badri Gechbaia** – Head of Department of Business Administration, Faculty of Economics and Business, Batumi Shota Rustaveli State University (Batumi) Georgia;
- Dr hab. (physical-mathematical sciences), Professor **Vyacheslav Kalashnikov** – ITESM, Campus Monterrey (Monterrey) México;
- Dr hab. (economic sciences), Professor **Sergii Kavun** – Rector of Kharkiv University of Technology «STEP» (Kharkiv) Ukraine;
- Dr hab. (legal sciences), Professor **Oksana Knyzhenko**, Department of Criminal Law and Criminology of Kharkiv National University of Internal Affairs (Kharkiv) Ukraine;
- Dr hab. (economic sciences), Professor **Inna Lazaryshyna** – Department of Accounting and Taxation of National University of Bioresources and Nature Management (Kyiv) Ukraine;
- Dr hab. (economic sciences), Professor **Iryna Migus** – Department of Finance, Accounting and Economic Security, Uman State Pedagogical University named after Pavlo Ty-chyna (Uman) Ukraine;
- Dr hab. (economic sciences), Professor **Liudmyla Matviichuk** – The Head of Department of Tourism and Civil Security of Lutsk National Technical University (Lutsk) Ukraine;
- Dr hab. (legal sciences), Associate Professor **Oleg Kyrychenko** – Head of the Department of Operative Investigatory Activity and Specialist Equipment of Dnipropetrovsk State University of Internal Affairs (Dnipropetrovsk) Ukraine;
- PhD (economic sciences), Professor **Dimiter G. Velez** – University of National and World Economy (Sofia), Bulgaria;
- The Chairman of the Student's Parliament – **Victoriia Yaroshchuk**, National University of Water and Environmental Engineering (Rivne) Ukraine.

Publisher: Cech Rzemiosł Różnych, Dr hab. (economic sciences), Professor **Zbigniew Sulżycki**,
72-600, ul. Bohaterów Września 4, Świnoujście, Polska,
email: ijonepaal@ukr.net, <http://www.ijoness.esy.es>.

Chief Editor: **Alina Yakymchuk**, Professor, Public Administration, Documentation and Information Activities Department of National University of Water and Environmental Engineering, 33028, Rivne, Soborna St., 11, Ukraine, email: ijonepaal@ukr.net, +380975981453.

Contents

I. Economics and Business.....	7
Kravchenko O. «Urgent» Investment as an Instrument for Ensuring Sustainable Financing for Infrastructure Projects	8
Kovshun N. The Influence of the Water System on the Balance of the Functioning of the National Economy.....	16
Kushnir N., Voitovych D. The Role of Financial Monitoring in the Management of Business Rehabilitation.....	35
Zubilevych S., Pozniakovska N., Miklukha O., Sirobinska A. Principles and Quality Characteristics of Accounting and Financial Statements Under National Legislation and Their Harmonization With International Standards and EU Directives.....	45
Akimova L. Improvement of the Evaluation of Economic Safety of State and Entities.....	55
II. Management, Security and Ecology.....	64
Yakymchuk A., Kupchyk L., Klimova A. State Regulation on Educational Activities in the EU Countries Exemplified by Accreditation of Study Programmes of Higher Education Institutions in Germany.....	65
Mironova M., Biletska H., Rybak V., Iefremova O., Shevchuk N., Shevchenko S., Artamonov B. Agroecological Assessment of Urboecosystems' Soils (Based on the Example of the City of Khmelnytskyi, Ukraine).....	72
Remyha Y. Economic Security in Supporting the Enterprise Strategic Development: Ukrainian View.....	85
Zochshuk V. The Analysis of the Production Troublesheet in the Production of Heat (on the Example of the Boiler House).....	95
Kostiukevych R., Kostiukevych A. Scientific and Methodical Approaches Transformation of the Mechanisms of Management Projects and Programs in the Field of Flood Protection of Territories	103
Michalczyk L. Economic Security in Supporting the Enterprise Strategic Development: Ukrainian View.....	113
III. International Relations and Regional Studies.....	121
Rogozńska-Mitrut J. Employee Resistance in Process of Changes...	122
Soboń J. The Influence of Globalization and European Integration on The Functioning of Polish Enterprises.....	128
Khumarova N. Dominantes of Water Resources Administrative Management in Ukraine	135
Pavlov K. Competition in Regional Housing Markets and Its Govern-	

ment Regulation.....	145
Melnyk L. External Experience of Organization of Mortgage Lending Agricultural Sphere.....	155
IV. Law and Public Administration.....	164
Balueva O., Ivanov G. The Legal Framework of the Territorial Community Interests Provision in the Process of the Seaport Development.....	165
Grygorak M., Isaienko I., Kuznietsova T. The Role of Artificial Intelligence in the Europeanization of Logistics Public Services.....	173
Ivanova N., Popova Y. Components of the Integrated Approach to Improving Organizational and Legal Mechanisms of State Governance of Food Safety of Ukraine.....	190
Simchuk T. Participatory Democracy in Action: Good Practices From Local Authorities of Oahu (HAWAII, USA).....	204
V. The Problems of Sociology and Pedagogy, Philosophy and Culture, Language and Medicine.....	213
Radchenko O., Lavrentev D. The Concept of Public-Private Partnerships as a Component of State Social Policy.....	214
Zoshchuk N. The Atrical Translations: Problems and Solutions.....	223
Skrypnikov A., Bodnar L., Shynder V. Methods of Treatment of Patients Suffering From Depressive Type of Schozoaffective Disorder	228
Biletska H., Mironova N., Mateyuk O., Kazimirova L., Diachuk A. Evaluation of Educational and Methodical Support in Natural Science Training of Future Ecologists.....	236
Martyshyn D. The role of the Ukrainian Christian Churches in the processes of development and strengthening of the Ukrainian state...	247
Petliovana L., Sukhovetska S. Peculiarities in Content-Based Approach to Teaching ESP.....	256



Dr.hab, Professor Andrii Skrypnikov
professorsan1963@gmail.com


ORCID: 0000-0002-7726-2178
Researcher ID: Q-1485-2018
SPIN: 7732-9040

PhD, Assoc. Prof. Lesya Bodnar
bod.lesya@gmail.com

ORCID: 0000-0002-1277-9344
Researcher ID: Q - 1815 - 2018
SPIN:3309-3843



Ukrainian Medical Stomatological Academy (Poltava, Ukraine)



PhD, Assoc. Prof. Viacheslav Shynder
dr.wenzeslav@gmail.com

https: 0000-0003-3140-7674
Researcher ID: Q-1302-2018
SPIN: 1642-3795

Poltava Regional Clinical Psychiatric Hospital named after O.F. Maltsev (Poltava, Ukraine)

METHODS OF TREATMENT OF PATIENTS SUFFERING FROM DEPRESSIVE TYPE OF SCHIZOAFFECTIVE DISORDER

TAKTYKA LECZENIA DEPRESYJNEGO RODZAJU ZABURZEŃ ZACHOWAWCZYCH

ТАКТИКА ЛЕЧЕНИЯ ДЕПРЕССИВНОГО ТИПА ШИЗОАФФЕКТИВНОГО РАСТРОЙСТВА

Abstract

The article presents the results of a comparative study of the therapeutic efficacy of atypical antipsychotics in combination with sertraline in the treatment of patients suffering from depressive type of schizoaffective disorder. The assessment of effectiveness was carried out using rating scales HAMD-21, PANSS and CGI-I. We observed a rather high clinical efficacy of drugs in the treatment of patients with depressive type of schizoaffective disorder and features of the spectrum of therapeutic effects on the indicated disorder. The results of the study showed that the drugs were well tolerated and did not show extrapyramidal disorders, facilitated the transition to remission and improved compliance between the physician and the patient.

A.Skrypnikov, L. Bodnar, V. Shynder

Keywords: *schizoaffective disorder, depressive type, risperidone, quetiapine, amisulpride, sertraline.*

Streszczenie

W pracy przedstawiono wyniki porównawczego badania skuteczności terapeutycznej atypowych leków przeciwpsychotycznych w połączeniu z sertralina w leczeniu zaburzeń schizoafektywnych typu depresyjnego. Ocenę skuteczności przeprowadzono z użyciem skali HAMD-21, PANSS i CGI-I. Stwierdzono, że skuteczność kliniczna leków jest wystarczająco wysoka w leczeniu pacjentów z zaburzeniem schizoafektywnym typu depresyjnego i cechami spektrum efektów terapeutycznych na niego. Wyniki badania wykazały, że leki były dobrze tolerowane i nie wykazywały dodatkowych zaburzeń piramidowych, ułatwiały remisję i zwiększały stopień komplikacji między lekarzem a pacjentem.

Słowa kluczowe: *zaburzenie schizoafektywne, typ depresyjny, rysperydon, kwetiapina, amisulpryd, sertralina.*

Аннотация

В работе представлены результаты сравнительного исследования терапевтической эффективности атипических антипсихотиков в сочетании с сертралином при терапии депрессивного типа шизоаффективного расстройства. Оценка эффективности проводилась с использованием оценочных шкал HAMD-21 PANSS и CGI-I. Констатирована достаточно высокая клиническая эффективность препаратов при лечении пациентов с депрессивным типом шизоаффективного расстройства и особенности спектра терапевтического воздействия на него. Результаты исследования показали, что препараты имели хорошую переносимость, способствовали выходу в ремиссию и улучшению комплайенса между врачом и пациентом.

Ключевые слова: *шизоаффективное расстройство, депрессивный тип, рисперидон, кветиапин, amisulприд, сертралин.*

Rationale. In recent years, diagnosis and psychopharmacotherapy of schizoaffective disorder (SAD) is one of the most widely discussed medical problem [1-2], as in connection with its prevalence among the population in Ukraine [3-5] and because of the difficulties of diagnosis [6-7].

The course of schizoaffective psychosis is characterized by episodic attack-like disorders, in which both affective and schizophrenic symptoms are present at the same time, wherein the mental disorder does not meet the criteria for either schizophrenia or manic-depressive psychosis [8-9].

The depressive type of schizoaffective disorder has a great medical and social significance, since it not only greatly enhances patient suffering, regardless of the degree of severity or stability of "positive" psychosymptoms, but also exacerbates the

disorder in psychosocial functioning and leads to attempted suicide or the completion of suicide [10]

A number of scientific papers describe the treatment of depressive type of schizoaffective psychosis using traditional (classical) neuroleptics with antidepressants [11]. However, most experts agree that the psychopharmacological treatment is the best and most promising with using the modern atypical antipsychotics in combination with antidepressants from a group of selective serotonin reuptake inhibitors (SSRIs) [12]. Despite the rapid development of psychopharmacotherapy and numerous studies of clinical manifestations, this problem remains extremely relevant and requires further research [13]. Data on the efficacy of atypical antipsychotics in combination with SSRIs in treatment depressive type of

schizoaffective disorder is still insufficient, so today there are no clear recommendations for practitioners regarding their using in the treatment of the specified pathology [14-15].

Goal of research is to study the therapeutic effectiveness of atypical antipsychotics from the group of risperidone, quetiapine, amisulpride in combination with antidepressant (sertraline) in the treatment of depressive type of schizoaffective disorder.

Materials and methods. In the study we included 54 patients of Poltava Regional Clinical Psychiatric Hospital named after OF Maltsev: 34 (62.96%) men and 20 (37.04%) women aged from 18 to 56 years old (average - $35,5 \pm 6,24$ years) with the duration of the disease from 1 month to 23 years. In accordance with the criteria of ICD-10, all patients suffered from schizoaffective disorder, depressive type (F 25.1). All patients were on inpatient treatment in the Poltava Regional Clinical Psychiatric Hospital named after OF Maltsev

The manifestation of SAD in 41 (75,93%) patients occurred in adulthood (after 20 years), in 13 (24,07%) patients - in youthhood (from 17 to 20 years).

The average age of patients with the manifestation of SAD was 27.9 ± 1.7 years. Duration of activity of the psychopathological process in patients was as follows: up to 1 month - 13 (24,07%), up to 2 months - 19 (35,19%), up to 3 months - 5 (9,26%) and more than 3 months - 17 (31,48%) persons. The average duration of the disease is 8.7 ± 7.4 years, the average number of previous hospitalizations is 6.4 ± 2.7 .

Patients were equally divided into 3 groups of 18 people each. Patients in the first group received orally risperidone, patients in the second group received quetiapine, patients in the third group received amisulpride. The prescription of the drugs was random. However, the groups did not differ statistically by gender, age, duration of the disease, psychopathological syndrome and severity of the condition of patients.

There was also no statistically significant difference in the basic clinical-demographic characteristics between the groups.

The criteria for inclusion in the study were: personal consent of the patient to participate in

the study, age from 18 years old, conformity of symptoms of depressive type of SAD to the criteria of heading F25.1 in ICD-10.

Exclusion criteria: absence of the personal consent of the patient to participate in the study, age up to 18 years, non-conformity of the disease symptoms to the criteria of heading F25.1 in ICD-10, increased sensitivity to the active component of medicinal products and their constituents, the presence of contraindications in accordance with the instructions for the use of medicines, pregnancy. We also excluded patients with productive symptomatology without concomitant affective disorders and patients treated with any depot-drugs or antipsychotic with prolonged action during the study period.

Risperidone or quetiapine, or amisulpride for the treatment of depressive type of SAD was administered in combination with sertraline.

Risperidone was orally administered according to the classical regimen in individual, clinically effective doses, starting with 2 mg in the first day. An effective therapeutic dose was selected by titration for 5-7 days before signs of positive clinical dynamics or side effects appeared. The maximum dose of risperidone in the study was 8 mg.

Patients with depressive type of SAD received quetiapine also orally or according to the classic regimen with an increase in dosage of 50 mg per day, or rapid increasing in 3-4 days according to a proven regimen: 200 → 400 → 600 mg.

Amisulpride was administered orally with titration of the dose and its gradual increase: on day 1 the daily dose was 50 mg, on day 2 the daily dose was 100 mg, and subsequently increased by 100 mg. The maximum daily dose of amisulpride in the study was 900 mg. In cases where the dosage did not exceed 400 mg, the drug was prescribed once a day. The higher dose was divided into two doses. We prescribed the drug in a therapeutic dose of 300-800 mg/day orally in 2 doses.

Sertraline, in combination with atypical antipsychotics, was administered orally at an initial dose of 50 mg/day. In cases with no decrease in the depressive affect of SAD, the dosage was increased once a week in a gradual

manner. The maximum daily dose of sertraline in the study did not exceed 100 mg.

In the case of psychomotor agitation or the emergence of extrapyramidal disorders in a patient, the temporary administration of benzodiazepine and anticholinergic drugs was admissible.

It should be noted that the prescription of sertraline in combination with atypical antipsychotics in the treatment of depressive type of SAD was due primarily to the attempt to decrease the manifestations of depressive component of the psychopathological structure in patients, as well as an attempt to achieve a deeper and more stable effect on the pathological process.

The assessment of patients' condition before the study was conducted using anamnestic, clinical and psychopathological and also psychodiagnostic examination using the Positive and Negative Syndrome Scale (PANSS) by Kay SR, Fiszbein A, Opler LA (1987), Hamilton (HAMD-21) to assess the severity of symptoms of depression (1967) and Clinical global impression-improvement (CGI-I) (1976). The assessment of the dynamics of mental status in patients with using of PANSS, HAMD-21 and CGI-I scales was performed at

the Week 2, 4 and 6 of treatment. In addition, daily in the study period, we measured the level of blood pressure and heart rate in our patients. Before the start of the experiment, all patients underwent a standard examination. The observation time was 6 weeks.

Study Results and Discussions. The final results of the study were analyzed in three groups and all 54 patients.

The average dose of risperidone during psychopharmacotherapy in patients in the first group was 5.42 ± 1.4 mg/day, quetiapine for patients in the second group - 476.6 ± 104 mg/day, amisulpride - 584.8 ± 214.6 mg/day Sertraline was prescribed in an average daily dose 84.2 ± 14.24 mg/day.

The survey revealed that before the inclusion in the study, the mean HAMD-21 score in patients of Group I receiving risperidone was 26.6, in patients of Group II receiving quetiapine - 28.2, and in patients of Group III receiving amisulpride - 26.9. On the PANSS scale in the category of positive symptoms, the average score in the Group I was 36.2, Group II - 33.4, Group III - 33.5.

The dynamics of the main indicators during the 6-week treatment period on the HAMD-21 scale is shown in table 1.

Table 1. The dynamics of indicators on the HAMD-21 scale

Duration of administration (weeks)	Group I (n = 18)	Group II (n = 18)	Group III (n = 18)
0	26.6	28.2	26.9
2	22.4	26.8	26.1
4	15.8	20.6	22.9
6	13.4	17.6	14.2
Difference between indicators before and after treatment	13.2	10.6	12.7

Note. * the difference is significant ($p < 0,05$) compared with the estimate before the start of therapy

** the difference is significant ($p < 0,05$) compared with the Group I

From Table 1 it can be seen that during the first 2 weeks of therapy, patients in all of the study groups had a slight reduction in depressive symptoms. The clear difference between these indicators on the scale between patients in all groups was found at Week 4, when the average score on HAMD-21 scale decreased to 15.8 in the Group I, 20.6 in the

Group II and 22.9 in the Group III. The statistically significant difference in evaluation was after 6 weeks of treatment, wherein the average score in the patients of the Group I was 13.4, Group II - 17.6, and Group III - 14.2. The difference in the indicators after 6 weeks of therapy compared with the indicators before treatment in the Group I was 13.2, in

the Group II - 10.6, in the Group III -12.7 ($p \leq 0.05$). This suggests that risperidone in combination with sertraline contributed to significant improvement of the affective area in patients with depressive type of schizoaffective disorder compared to

quetiapine, while amisulpride on the HAMD-21 scale was intermediate but no statistically significant difference between risperidone and amisulpride was observed.

The survey results on the scale PANSS of positive syndromes are shown in table 2.

Table 2. Dynamics of indicators on the scale PANSS of positive syndromes

Duration of administration (weeks)	Group I (n = 18)	Group II (n = 18)	Group III (n = 18)
0	35.2	35.5	34.9
2	31.5	27.9	29.6
4	28.3	23.1	24.4
6	18.6	16.2	19.3
Difference between indicators before and after treatment	16.6	19.3	15.6

The conducted study showed that during the 6-week period of psychopharmacotherapy the indicators of positive syndromes tended to decrease, while in the Group II and Group III the reduction of positive pathopsychological symptoms was more rapid, more uniform and more signified in comparison with the Group I. It was also noted that in the above-mentioned groups, the decrease in the severity

of positive syndromes occurred at the Week 2 of therapy. The final difference in the "effectiveness" of the effect on the psychopathological symptoms between amisulpride and riseridone was 1.0, between amisulpride and quetiapine - 3.7, between quetiapine and risperidone - 2.7.

The survey results on the scale PANSS of negative syndromes are shown in table 3.

Table 3. Dynamics of indicators on the scale PANSS of negative syndromes

Duration of psychopharmacotherapy (weeks)	Group I (n = 18)	Group II (n = 18)	Group III (n = 18)
0	3.7	3.8	4.2
2	3.6	3.8	3.9
4	3.5	3.5	3.6
6	3.4	3.3	3.5
Difference between indicators before and after treatment	0.3	0.5	0.7

Table 3 shows that during the entire period of treatment, low rates of negative syndromes had a slight tendency to decrease.

In general, the clear antipsychotic effectiveness of the drugs was observed at the Week 2 of therapy with a tendency for further reduction of psychopathological symptoms. Thus, amisulpride and quetiapine in the above-mentioned doses had a more significant effect on productive symptoms, in combination with

an unstable affection in the form of anxiety and agitation, while risperidone exhibited antipsychotic effects in combination with a sufficiently rapid reduction of depressive symptoms. In the clinical picture, patients in the studied groups initially had a decrease in the intensity of productive symptoms with a gradual decrease in social isolation and suspicion. Improvement of social adaptation with the expansion of the circle of contacts,

the desire and ability to establish interpersonal contacts took place during 2 months of treatment. One patient in the Group I with inadequate increase in activity had activation. In the Group II, in two cases, we observed the orthostatic syndrome, and in one case, we observed psychomotor agitation with an increase in verbal hallucinatory symptomatology.

According to the SGI-I scale, there was no statistically significant difference between the study groups. In general, we observed a significant improvement in the condition of 35 (64.81%) patients with the reduction of psychopathological symptoms, improvement of cognitive and communication functions. Patients actively participated in rehabilitation actions with social activity. In 14 (25.93%) patients we observed moderate improvement of the mental condition and subjective state of health during treatment, reduction of psychopathological symptoms, decrease in the severity of depression and paranoid syndrome. After treatment in 5 (9.26%) patients the condition was slightly improved. Among them there were 2 patients with stable hypochondriacal depression. In one patient, suicidal intent was remained. Two patients had the residual delusional ideas of inadequacy and insufficiency.

Conclusions. Thus, risperidone in combination with sertraline in the treatment of a depressive type of schizoaffective disorder promotes a faster and deeper reduction of depressive symptoms, but this combination weakens the hallucinatory and delusional psychosymptoms more slowly. This combination is characterized by a wide spectrum of antipsychotic activity, does not cause excessive sedation and uniformly contributes to the reduction of various manifestations of depressive and paranoid conditions.

Quetiapine in combination therapy with sertraline promotes faster and deeper reduction of hallucinatory and delusional syndrome compared with depression. In many clinical studies, quetiapine had a sedative effect, reducing aggressiveness in the acute phase of psychosis.

Amisulprid was characterized by a more significant effect on paranoid symptoms, while the weakening of positive syndromes was faster and uniform. Also, amisulprid contributed to the improvement of the affection. The reducing of hallucinatory symptoms was gradual and uniform, with no significant difference in all groups.

Bibliography:

1. Скрипніков А. М. Фармакотерапія афективних порушень депресивного регістру у хворих на епілептичну хворобу з сексуальною дисфункцією / А. М. Скрипніков, Г. Т. Сонник, Л. В. Животовська, В. В. Шиндер // Таврический журнал психиатрии. – 2012. – Т.16, №3 (60). – С.62 – 65.
2. Скрипніков А. М. Ефективність та безпечність агомелатину в якості додаткового препарату у пацієнтів з епілептичною хворобою та сексуальною дисфункцією / А. М. Скрипніков, Г. Т. Сонник, В. В. Шиндер // Український вісник психоневрології. – 2012. – Т.20, вип. 3 (72). – С. 138.
3. Животовська, Л.В. Оцінка якості життя при проведенні комплексної терапії у хворих на перший психотичний епізод з урахуванням біоритмологічного статусу / Л.В. Животовська, Д.І.Бойко, В.В. Шиндер, // Wiadomosci Lekarskie. - 2017. - Т.70,cz I. - № 3. – С. 524.
4. Шиндер В. В. Ефективність атипичних антипсихотиків у поєднанні з антидепресантом при терапії депресивного типу шизоафективного розладу / В. В. Шиндер // Медична психологія. – 2017. – Т. 12, № 2 (46). — С. 73–76.
5. Животовська Л. В. Оцінка ефективності лікувально-реабілітаційних заходів у пацієнтів з першим психотичним епізодом з урахуванням біологічних ритмів / Л. В. Животовська, Д. І. Бойко, Л. А. Боднар, В. В. Шиндер // Science Rise:Medical science. – 2017. – № 3 (11). – С. 15–19.
6. Скрипніков, А. М. Фармакотерапія депресивно-параноїдних станів у хворих на шизофренію / А.М. Скрипніков, Л.В. Животовська, В.В. Шиндер // Вісник психіатрії та психофармакотерапії. – 2010. - № 1(17) - С.104-108.
7. Скрипніков, А. М. Порівняльна характеристика терапевтичної ефективності рисперону та кветирону при лікуванні депресивно-параноїдних станів у хворих на шизофренію / А.М. Скрипніков, В.В. Шиндер// Вісник Української медичної стоматологічної академії. “Актуальні проблеми сучасної медицини”. – 2010. – Т. 10, №2. (30). - С.105-109.

8. Скрипніков А.М. Рациональний підхід до застосування генеричних атипичних антипсихотиків (рисперону та кветирону) в лікуванні депресивно-параноїдних станів у хворих на шизофренію / А.М. Скрипніков, В. В. Шиндер // Матеріали науково-практичної конференції «Сучасні методи лікування захворювань пси- хогенного походження» (XIII Платонівські читання), (24 — 25 червня 2010 року, м. Харків, клінічний санаторій «Курорт Березівські мінеральні води»), X., 2010. — С. 215-216.
9. Боднар Л.А. Клініко-психопатологічні та патопсихологічні характеристики пацієнтів, які зверталися до пластичних хірургів для проведення ринопластики / Л.А. Боднар // Психічне здоров'я. — 2011. — Випуск 1-2 (30-31). — С. 4-7.
10. Шиндер В. В. Особистісні особливості подружніх пар з епілепсією в чоловіка та їх вплив на розвиток в них сексуальної дисгармонії / В.В. Шиндер // Медична психологія. — 2013.- Т. 8, №2 (30). — С.112-116.
11. Скрипніков А. М. Сексуальна дисгармонія подружньої пари, в якій чоловік хворіє епілепсією, та вплив біологічних ритмів на її перебіг / А. М. Скрипніков, Л. О. Герасименко, В. В. Шиндер // Психічне здоров'я. — 2013. — №1 —2 (38 — 39). — С. 22 — 25.
12. Шиндер В. В. Роль циркадіанних ритмів у патогенезі сексуальної дисгармонії подружньої пари, в якій чоловік хворіє на епілепсію / В. В. Шиндер // Світ медицини та біології. — 2013. — № 2 (38). — С. 188 — 190.
13. Шиндер В. В. Порівняльна характеристика соматостатевого розвитку подружніх пар, в яких чоловік хворіє на епілепсію та має місце сексуальна дисгармонія / В. В. Шиндер // Український вісник психоневрології. — 2013. — Т.21, вип. 1 (74). — С.100 — 102.
14. Шиндер В. В. Феноменологія епілептичної хвороби та її вплив на сексуальну функцію в чоловіка / В. В. Шиндер// Актуальні проблеми сучасної медицини : вісник Української медичної стоматологічної академії. — 2013. — Т.13, вип. 2 (42). — С. 279 — 282.
15. Шиндер В.В. Особливості психосексуального розвитку подружніх пар у разі епілепсії у чоловіка в аспекті формування у них сексуальної дисгармонії / В.В. Шиндер // Лікарська справа (Врачебное дело). — 2014. — № 1-2. — С. 129 — 133.

References:

1. Skrypnikov, A.M., Sonnik, G.T., Zhivotovskaya, L.V. and Schynder, V.V., (2012), "Pharmacotherapy of affective disorders of the depressive register in patients with epileptic disease with sexual dysfunction", *Tavrishesky journal of psychiatry*, vol.16, no 3, pp. 62 - 65.
2. Skrypnikov, A.M., Sonnik, G.T. and .Shynder, V.V., (2012) , "Efficiency and safety of agomelatine as an additional drug in patients with epileptic disease and sexual dysfunction", *Ukrainian Bulletin of Psychoneurology*, vol. 20, no 3, pp. 138.
3. Zhivotovska, L.V., Boyko, D.I, and Shynder, V.V., (2017), "Assessment of quality of life in the course of complex therapy in patients with the first psychotic episode, taking into account biorhythmological status", *Wiadomosci Lekarskie*, vol.70, no 3, pp. 524.
4. Shynder, V.V., (2017), "Efficiency of atypical antipsychotics in combination with antidepressant in the treatment of depressive type of schizoaffective disorder", *Medical psychology*, vol.12, no 2, pp. 73-76.
5. Zhivotovska, L.V., D.I. Boyko, L.A. Bodnar, and Shynder, V.V., (2017), "Evaluation of the effectiveness of treatment and rehabilitation measures in patients with a first psychotic episode taking into account biological rhythms", *Science Rise: Medical science*, no 3, pp. 15-19.
6. Skrypnikov, A.M., Zhivotovskaya, L.V., and Schynder V.V., (2010), "Pharmacotherapy of depressive-paranoid states in patients with schizophrenia", *Bulletin of Psychiatry and Psychopharmacotherapy*, no 1, pp. 104-108.
7. Skripnikov, A.M. and Schynder V.V., (2010), "Comparative analysis of therapeutic efficacy of risperone and kветironu in the treatment of depressive-paranoid states in patients with schizophrenia" *Bulletin of the Ukrainian medical the dental Academy. "Actual problems of modern medicine"*, vol.10, no 2, pp.105-109.
8. Skripnikov, A.M. and Schynder, V.V., (2010), "A rational approach to the use of generic atypical antipsychotics (risperone and quetiron) in the treatment of depressive and paranoid states in patients with schizophrenia", *Modern methods of treating diseases of psychogenic origin (XIII Platonovsky reading): materials of the scientific-practical conference*, Clinical sanatorium "Resort Berезivsky mineral waters", Kharkiv, Ukraine, June 24-25, 2010, pp. 215-216.
9. Bodnar, L.A., (2011), "Clinical, psychopathological and pathopsychological characteristics of patients who turned to plastic surgeons for rhinoplasty", *Mental health*, no 1-2, pp. 4-7.

10. Shynder V.V., (2013), "The influence of personality characteristics on sexual disharmony development in couples with epilepsy husband", *Medical psychology*, vol. 8. no 2, pp. 112-116.

11. Skrypnykov, A.M., Gerasymenko, L.O. and Shynder V.V., (2013), "Sexual disharmony of married couple, where a husband has epilepsy and influence of biological rhythms on its flow", *Mental health*, no 1-2 (38-39), pp.22-25.

12. Shynder, V.V., (2013), "Circadian rhythm's role in sexual disharmony patogenesis of couple, in which husband suffer from epilepsy", *World of Medicine and Biology*, no. 2 (38), pp. 188 - 190.

13. Shynder, V.V. (2013), "The comparative characteristic of bodily and sexual development of married couples, where a husband has epilepsy and where sexual disharmony takes place", *Ukrainian Bulletin of Psychoneurology*, no. 1 (74), pp.100 - 102.

14. Shynder, V.V., (2013), "Phenomenology of epilepsy and its impact on sexual function in men" *Current problems of modern medicine: the bulletin of the Ukrainian Medical Stomatological Academy*, vol.13, pp.279-282.

15. Shynder, V.V., (2014), "Features of the psychosexual development of married couples with epilepsy at the husband in aspect of formation at them sexual disharmony", *Medical Practice*, no. 1-2, P. 129 - 133.